Dr. Andrew L. Pecora, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 336
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NJ license 25MA05277400 -
Hematology (Internal Medicine) Physician
NJ license 25MA05277400
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hackensack University Medical Center Hackensack, NJ
- Jersey Shore University Medical Center Neptune, NJ
- Ocean Medical Center Brick, NJ
- Riverview Medical Center Red Bank, NJ
Medical groups
- Regional Cancer Care Associates LLC (151 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 336
- Services billed
- 16,179
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 539 | 233 |
| Established patient office or other outpatient visit, 40-54 minutes | 525 | 118 |
| New patient office or other outpatient visit, 60-74 minutes | 77 | 77 |
| Established patient office or other outpatient visit, 20-29 minutes | 41 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocortisone Other prescribers in Hackensack, NJ | 85 |
| Prednisone Other prescribers in Hackensack, NJ | 65 |
| Levothyroxine Sodium Other prescribers in Hackensack, NJ | 51 |
| Tafinlar (dabrafenib mesylate) | 32 |
| Mekinist (trametinib dimethyl sulfoxide) | 30 |
| Ondansetron Hcl Other prescribers in Hackensack, NJ | 23 |
| Erivedge (vismodegib) | 18 |
| Anastrozole Other prescribers in Hackensack, NJ | 17 |
| Hydrochlorothiazide Other prescribers in Hackensack, NJ | 13 |
| Furosemide Other prescribers in Hackensack, NJ | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $743,981 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Sta…
Merck Sharp & Dohme LLC - A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals, Inc. · Terminated · NCT04916002 - An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
ModernaTX, Inc. · Active, not recruiting · NCT03897881 - A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916 - A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [RELAtivity-098]
E.r. Squibb & Sons, L.l.c. - A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma
E.r. Squibb & Sons, L.l.c. - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence
E.r. Squibb & Sons, L.l.c. - Brightline-4
Boehringer Ingelheim Pharmaceuticals, Inc. - Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.